{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:25:41Z","timestamp":1787509541504,"version":"build-2736575974"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["10211476"],"award-info":[{"award-number":["10211476"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PolyU grant","award":["P0035514"],"award-info":[{"award-number":["P0035514"]}]},{"name":"PolyU grant","award":["P0034099"],"award-info":[{"award-number":["P0034099"]}]},{"name":"Research Centre for SHARP Vision","award":["P0039545"],"award-info":[{"award-number":["P0039545"]}]},{"DOI":"10.13039\/501100017649","name":"Hong Kong Government","doi-asserted-by":"publisher","award":["InnoHK and Hong Kong Special Administrative Region Government"],"award-info":[{"award-number":["InnoHK and Hong Kong Special Administrative Region Government"]}],"id":[{"id":"10.13039\/501100017649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myopia, characterized by excessive axial elongation of the eyeball, increases risks of having sight-threatening diseases and impose a financial burden to healthcare system. Although myopic control interventions showed their effectiveness in slowing progression, the efficacy varies between individuals and does not completely halt progression. The study aims to investigate the efficacy of combining 0.01% atropine administered twice daily with optical defocus for myopia control in schoolchildren.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>This is a prospective, parallel-group, single-blinded, randomized, active-control trial (ClinicalTrials.gov identifier: NCT06358755). Myopic schoolchildren with no previous myopic control interventions aged between 7 to 12 years will be recruited. They will be randomly allocated into two groups (n = 56 per group) after baseline measurement. Both groups will receive 0.01% atropine twice per day for 18 months (one drop in the morning and the other drop at night before bedtime). Defocus incorporated multiple segments (DIMS) spectacle lenses will be prescribed in atropine plus optical defocus (ATD) treatment group while single vision spectacle lenses will be given in atropine only (AT) group. Cycloplegic refraction and axial lengths will be monitored every 6 months over 18-month study period. The primary outcomes are changes in cycloplegic refraction and axial lengths relative to the baseline over the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The result will examine the combination effect of low dose atropine and myopic defocus on myopia control in a randomized controlled study. The findings will also explore the potential benefits of applying 0.01% atropine twice per day on myopic control and its potential side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0306050","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T13:40:44Z","timestamp":1719409244000},"page":"e0306050","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination effect of optical defocus and low dose atropine in myopia control: Study protocol for a randomized clinical trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-0963","authenticated-orcid":true,"given":"Rachel Ka Man","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Kin","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kryshell Yu Qi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Ho","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-2941","authenticated-orcid":true,"given":"Kendrick C.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Kai Shun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Yan Yin","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"9827","key":"pone.0306050.ref001","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"IG Morgan","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"pone.0306050.ref002","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"BA Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"pone.0306050.ref003","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0161-6420(99)90416-5","article-title":"The relationship between glaucoma and myopia: the Blue Mountains Eye Study","volume":"106","author":"P Mitchell","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0306050.ref004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications.","volume":"25","author":"SM Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"issue":"12","key":"pone.0306050.ref005","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1167\/iovs.13-12795","article-title":"The economic cost of myopia in adults aged over 40 years in Singapore","volume":"54","author":"YF Zheng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0306050.ref006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI Prevention of Myopia and Its Progression","volume":"62","author":"JB Jonas","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"pone.0306050.ref007","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1167\/iovs.07-0383","article-title":"Simultaneous defocus integration during refractive development","volume":"48","author":"DY Tse","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"pone.0306050.ref008","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1167\/iovs.13-11724","article-title":"Integration of defocus by dual power Fresnel lenses inhibits myopia in the mammalian eye","volume":"55","author":"SA McFadden","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0306050.ref009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/bjophthalmol-2013-303914","article-title":"Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial.","volume":"98","author":"CS Lam","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"pone.0306050.ref010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","article-title":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.","volume":"104","author":"CSY Lam","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"pone.0306050.ref011","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"WH Chua","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0306050.ref012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.","volume":"126","author":"JC Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0306050.ref013","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/opo.13259","article-title":"Myopia progression patterns among paediatric patients in a clinical setting.","volume":"44","author":"M Moore","year":"2024","journal-title":"Ophthalmic Physiol Opt"},{"issue":"2","key":"pone.0306050.ref014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"A Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0306050.ref015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/opo.12722","article-title":"One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial.","volume":"40","author":"Q Tan","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"key":"pone.0306050.ref016","article-title":"Comparison of the long-term effects of atropine in combination with Orthokeratology and defocus incorporated multiple segment lenses for myopia control in Chinese children and adolescents.","author":"T Tang","year":"2024","journal-title":"Eye (Lond)."},{"issue":"1","key":"pone.0306050.ref017","doi-asserted-by":"crossref","first-page":"22311","DOI":"10.1038\/s41598-022-25599-z","article-title":"Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia.","volume":"12","author":"Z Huang","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0306050.ref018","doi-asserted-by":"crossref","first-page":"e0281816","DOI":"10.1371\/journal.pone.0281816","article-title":"A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine.","volume":"18","author":"P Nucci","year":"2023","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T13:41:01Z","timestamp":1719409261000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306050"}},"subtitle":[],"editor":[{"given":"Johanna","family":"Pruller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306050","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}